Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: A pilot study

Journal of Immunotherapy

Volumn 35, Issue 2, 2012, Pages 196-204

  Wright, Stephen E ^a,b,c,e,f   Rewers Felkins, Kathleen A ^a,b,c,f   Quinlin, Imelda S ^a,b,c,f   Phillips, Catherine A ^a,b,c   Townsend, Mary ^g   Philip, Ramila ⁱ   Dobrzanski, Mark J ^c   Lockwood Cooke, Pamela R ^h   Robinson, William ^d,f  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b Women's Health and Research Institute   (United States)

^c Department of Internal Medicine ^*  (United States)

^d TEXAS TECH UNIVERSITY   (United States)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^f Harrington Cancer Center   (United States)

^g Coffee Memorial Blood Bank ^*  (United States)

^h WEST TEXAS A AND M UNIVERSITY   (United States)

ⁱ Immunotope Inc   (United States)

Author keywords

adoptive immunotherapy; CTL; human; MUC1; stimulation

Indexed keywords

CA 125 ANTIGEN; MUCIN 1; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DONOR LYMPHOCYTE INFUSION; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; KILLER CELL; LEUKAPHERESIS; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; OVARY CANCER; PERITONEAL CAVITY; PILOT STUDY; PRIORITY JOURNAL; RECURRENT CANCER;

CA-125 ANTIGEN; FEMALE; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; MUCIN-1; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PILOT PROJECTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84856834217     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318243f213     Document Type: Article

References (36)

1. Cannistra SA, Gershenson DM, Recht A. Ovarian cancer, fallopian tube carcinoma, and pertoneal carcinoma. In: DeVita VTJ, Lawrence TS, Rosenburg SA, eds. Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2008:1568-1594.
2. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: A pilot trial. J Immunother Emphasis Tumor Immunol. 1994;16:198-210. (Pubitemid 24321452)
3. Canevari S, Stoter G, Arienti F, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst. 1995;87:1463-1469.
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5: 263-274. (Pubitemid 40488632)
5. Straathof KCM, Bollard CM, Popat U, et al. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood. 2005;105:1898-1904. Epub 2004 Nov 12. (Pubitemid 40731770)
6. Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 2007;92:72-80. (Pubitemid 46232660)
7. Toh U, Yamana H, Sueyoshi S, et al. Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res. 2000;6:4663-4673. (Pubitemid 32110403)
8. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239. [Epub 2008 Sep 22].
9. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168-16173. (Pubitemid 35462767)
10. Wright SE, Kilinski L, Talib S, et al. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by nativeMUC1 mucin and a mucin peptide mutated at a glycosylation site. J Immunother. 2000;23:2-10. (Pubitemid 30079820)
11. Ioannides CG, Fisk B, Jerome KR, et al. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993;151:3693-3703. (Pubitemid 23282681)
12. Wright SE, Khaznadar R, Wang Z, et al. Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand J Immunol. 2008;67:24-29. (Pubitemid 350209581)
13. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. Tumor burden influences cytotoxic T cell development in metastatic breast cancer patients-a phase I/II study. Immunol Invest. 2009; 38:820-838.
14. Ross S, Osband M. Treatment of metastatic renal cell carcinoma (RCC) with autloymphocyte therapy. Correlation between survival and the number of infused lymphocytes. FASEB J. 1989;3(3, Part 1):A825; abstract 3482.
15. Quinlin IS, Burnside JS, Dombrowski KE, et al. Context of MUC1 epitope: Immunogenicity. Oncol Rep. 2007;17: 453-456.
16. Dobrzanski MJ, Reome JB, Hylind JC, et al. CD8-mediated type 1 antitumor responses selectively modulate endogenous differentiated and nondifferentiated T cell localization, activation, and function in progressive breast cancer. J Immunol. 2006;177:8191-8201. (Pubitemid 44846340)
17. Barnd DL, Lan MS, Metzgar RS, et al. Specific, major histocompatibility complex-unrestricted recognition of tumorassociated mucins by human cytotoxic T cells. Proc Natl Acad Sci U S A. 1989;86:7159-7163. (Pubitemid 19240884)
18. Roehm NW, Rodgers GH, Hatfield SM, et al. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods. 1991; 142:257-265.
19. Kornbluth J, Flomenberg N, Dupont B. Cell surface phenotype of a cloned line of natural killer cells. J Immunol. 1982; 129:2831-2837. (Pubitemid 13245567)
20. von Zons P, Crowley-Nowick P, Friberg D, et al. Comparison of europium and chromium release assays: Cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin Diagn Lab Immunol. 1997;4:202-207. (Pubitemid 27130234)
21. Cancer Therapy Evaluation Program, DCTD, NCI, NIH, DHHS. Common Toxicity Criteria, Version 2.0 (CTC). March 23, 1998. Available at http://ctep.info.nih. gov/reporting/ctc. html. Accessed April 30, 1999.
22. Wright SE, Rewers-Felkins KA, Quinlin IS, et al. MHCunrestricted lysis ofMUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest. 2008;37:215-225. (Pubitemid 351499572)
23. Alajez NM, Schmielau J, Alter MD, et al. Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood. 2005;105:4583-4589. (Pubitemid 40807275)
24. Apostolopoulos V, Barnes N, Pietersz GA, et al. Ex vivo targeting of the macrophage mannose receptor generates antitumor CTL responses. Vaccine. 2000;18:3174-3184. (Pubitemid 30348658)
25. Hiltbold EM, Ciborowski P, Finn OJ. Naturally processed class II epitope from the tumor antigen MUC1 primes human CD4+ T cells. Cancer Res. 1998;58:5066-5070. (Pubitemid 28521162)
26. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100:27-32. (Pubitemid 41815045)
27. Bernhard H, Neudorfer J, Gebhard K, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 2008;57:271-280. (Pubitemid 350159915)
28. Meidenbauer N, Marienhagen J, Laumer M, et al. Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J Immunol. 2003;170:2161-2169. (Pubitemid 36197440)
29. Mackensen A, Meidenbauer N, Vogl S, et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24:5060-5069. (Pubitemid 46631410)
30. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175:7046-7052. (Pubitemid 41598952)
31. Loveland BE, Zhao A, White S, et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: A phase I trial in patients with adenocarcinoma. Clin Cancer Res. 2006;12:869-877. (Pubitemid 43259870)
32. Habib-Agahi M, Phan TT, Searle PF. Co-stimulation with 4- 1BB ligand allows extended T-cell proliferation, synergizes with CD80/CD86 and can reactivate anergic T cells. Int Immunol. 2007;19:1383-1394. [Epub 2007 Oct 31]. (Pubitemid 350131344)
33. Rudolf D, Silberzahn T, Walter S, et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol Immunother. 2008;57:175-183. Epub 2007 Jul 27. (Pubitemid 350159919)
34. Prenndergast GC, Jaffee EM. Cancer Immunotherapy: Immune Suppression and Tumor Growth. Amsterdam: Academic Press/ Elsevier; 2007.
35. Dobrzanski MJ, Rewers-Felkins KA, Quinlin IS, et al. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival. Clin Immunol. 2009;133:333-352.
36. Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453-1464.